{"entity":{"id":"granisetron","kind":"drug","name":"Granisetron","aka":["Granisetron hydrochloride","Granisetron transdermal system","Granisetron extended-release injection"],"tldr":"Granisetron is an anti-sickness medicine for chemotherapy given as a tablet, an injection, a week-long skin patch (Sancuso) or a slow-release injection that lasts several days (Sustol).","summary":"Granisetron (Kytril) was approved in December 1993 for prevention of nausea and vomiting from emetogenic chemotherapy, with tablets and a radiotherapy indication following; oral and intravenous granisetron are now generic. Two formulations extended its reach: the Sancuso transdermal patch (2008) applied 24 to 48 hours before chemotherapy and worn for up to seven days for regimens of up to five consecutive days, and Sustol (2016), a polymer-based extended-release subcutaneous injection that maintains levels for at least five days and is approved with other antiemetics for acute and delayed nausea and vomiting after moderately emetogenic or anthracycline-cyclophosphamide chemotherapy. The EU authorised Sancuso in 2012. Headache and constipation are the class effects; QT prolongation is less than with dolasetron.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Granisetron","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=granisetron"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/granisetron"},{"label":"NCI page (granisetron hydrochloride)","url":"https://www.cancer.gov/about-cancer/treatment/drugs/granisetronhydrochloride"},{"label":"EPAR (Sancuso)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso"}],"tags":["nci-list","supportive","generic"],"related":["ondansetron","palonosetron"],"cancers":[],"sections":[],"technologies":["antiemetic-therapy"],"targets":[],"drugs":[],"companies":["heron-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00186628"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Kytril (historic) / Sancuso / Sustol","modality":"5-HT3 receptor antagonist (antiemetic)","supportive":true,"mechanism":"Selective serotonin 5-HT3 receptor antagonist acting on vagal afferents in the gut and the chemoreceptor trigger zone.","approvals":[{"region":"US","year":1993,"indication":"Prevention of nausea and vomiting from emetogenic chemotherapy (Kytril; radiotherapy later)"},{"region":"US","year":2008,"indication":"Transdermal system for chemotherapy of up to five consecutive days (Sancuso)"},{"region":"US","year":2016,"indication":"Extended-release injection for acute and delayed nausea and vomiting with moderately emetogenic or anthracycline-cyclophosphamide chemotherapy (Sustol)"},{"region":"EU","year":2012,"indication":"Transdermal granisetron for moderately or highly emetogenic chemotherapy (Sancuso)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/granisetron/","neighbours":{"drug":[{"id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/"},{"id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/"},{"id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/"}],"technology":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"}],"company":[{"id":"heron-therapeutics","kind":"company","name":"Heron Therapeutics","route":"/companies/heron-therapeutics/"}],"trial":[{"id":"nct00186628","kind":"trial","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","route":"/trials/nct00186628/"},{"id":"ts-p04834","kind":"trial","name":"Study 3 (rolapitant, moderately emetogenic chemotherapy)","route":"/trials/ts-p04834/"}],"target":[{"id":"htr3a","kind":"target","name":"5-HT3 receptor (HTR3A)","route":"/targets/htr3a/"}]}}